What is thymosin alpha-1?

• What thymosin alpha-1 actually is: a 28-amino-acid prothymosin alpha fragment, not TB-500
• How it rebalances immunity through T-cell maturation, Th1 polarization, and dendritic-cell TLR signaling
• Where the evidence is real (the hepatitis B trials) and where pivotal trials came up neutral or negative
• Its regulatory reality: one verifiable foreign registration, no FDA approval, and no authorization for US compounding

1. 01 What is thymosin alpha-1? An immune-rebalancing peptide, registered abroad and misunderstood everywhere free
2. 02 Discovery and origins From a crude thymus extract to a synthetic immune drug paid
3. 03 The molecule: structure and chemistry Twenty-eight acidic residues with an acetyl cap paid
4. 04 How it works: the immune mechanism Maturing T cells, priming dendritic cells, rebalancing tone paid
5. 05 Not TB-500: the mandatory disambiguation Same prefix, different molecule, different everything paid
6. 06 The hepatitis evidence A real but small, delayed, and inconsistent effect paid
7. 07 Critical illness: sepsis and COVID-19 Where the best trials turned neutral paid
8. 08 Cancer adjuvant and vaccine support Immune support around cancer and vaccination paid
9. 09 Dosing and administration How it is given, and why the numbers are education only paid
10. 10 Safety, side effects and regulation Well tolerated in trials, unauthorized at the pharmacy paid
11. 11 Final exam and certification Pass the final exam to earn your certificate of completion. Exam

Thymosin alpha-1 is a small fragment of a much larger protein. The body cuts the first 28 amino acids off a nuclear protein called prothymosin alpha, and the acetyl cap at the front comes with them: the parent is already acetylated on its own N-terminal serine, so the fragment inherits the cap. That short, acidic, acetylated peptide is Tα1, and the marketed drug is a chemically synthesized copy of it.

Two features define it. First, it is a fragment, not a standalone gene product, which is why its exact physiological source is still debated. Second, it behaves as a signal, priming immune cells rather than acting as a classic hormone or growth factor. Keep both in mind, because they explain its gentle, wide-ranging effects.

The single most important idea in this course is that Tα1 does not just boost immunity. It behaves like a rheostat that restores balance in a dysregulated system, augmenting a deficient response and calming an excessive one. There is no single high-affinity receptor; several converging pathways produce that balancing behavior.

Because it works across several levers at modest strength, Tα1 is best understood as a context-dependent balancer. That breadth is why it has been trialed in such different diseases, and also why pinning down a single clean effect has been so hard. Hold that tension; it recurs throughout the course.

The most common error in peptide-community content is treating thymosin alpha-1 and TB-500 as versions of the same thing. They are not. TB-500 is a fragment of thymosin beta-4, a completely different peptide with a different length, sequence, mechanism, and purpose. A full unit covers this later; the preview matters now so nothing that follows is misread.

The only real link is history: both were first separated from the same crude thymus extract and both carry the word "thymosin." Beyond that shared name, they are different molecules doing different jobs. Calling them interchangeable or stackable equivalents is simply a factual error.

Tα1 occupies an unusual regulatory position, and the usual summary of it is not quite right. Reviews repeat that Zadaxin / thymalfasin is approved in more than 35 countries for hepatitis B and C, but that figure traces back to a manufacturer annual report rather than to any regulatory record, and when the FDA reviewed the same claim in 2024 it said it was unable to independently verify approval in the countries specified. The one foreign registration that can be read in a regulator's own document is the Italian one, granted in 1996, and its authorized use is as an adjuvant to influenza vaccination in immunocompromised adults, not hepatitis. In the United States there is no marketing approval at all, only orphan designations, and the peptide circulates through compounding and research-peptide channels.

This split is not a technicality. An orphan designation is a development incentive, not an efficacy endorsement, and it is frequently misrepresented as "FDA recognition." Where Tα1 is registered, a patient gets a controlled product; where it is not, a buyer gets an unverified vial. Same molecule, very different guarantees.

Before any deeper science, here is the honest picture, tiered by strength. The mechanism is well replicated across international labs. The hepatitis use, the indication the manufacturer reports registrations for, rests on real but inconsistent randomized trials. And the high-profile sepsis and COVID-19 claims are precisely where the largest, best-designed studies turned neutral or mixed. Keeping these three tiers strictly apart, rather than blurring them into one hopeful story, is the whole point of this course.

A few specific claims you will meet online, held against the evidence tiers above. Notice the pattern: the claims are usually not fabricated so much as rounded up, taking a modest, single-region, or observational signal and presenting it as settled fact.

Reading each claim against its actual evidence tier is exactly the skill this course builds. Some, like the excellent tolerability, hold up reasonably well; others, like the sepsis and TB-500 claims, collapse on contact with the primary literature. The next units give you the detail to do this yourself.